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Abstract Background and Study Aims Perioperative use of anticoagulant and platelet-inhibit-
ing agents by patients undergoing spine surgery poses the dilemma of increased risk of
hemorrhage. We examined the standards of use for these medications and expert
opinions through a nationwide survey.
Materials and Methods An online-based survey was conducted by invitation.
A personal token to access the survey was sent to one representative of each
neurosurgical and orthopaedic unit performing spine surgery and to all other active
members of the Swiss Society of Neurosurgery and the Swiss Society of Spinal Surgery.
A total of 97 e-mail invitations were sent to 19 representatives of neurosurgical or
orthopaedic units and 78 registered neurosurgeons and orthopaedic surgeons who
potentially perform spine surgery.
Results From February to April 2016, 40 surgeons (26 neurosurgeons, 14 orthopaedic
surgeons) completed the survey (41%). Among the respondents, 55% prescribed prophy-
lactic heparin preoperatively; depending on the procedure, 83 to 95% prescribed heparin
postoperatively. Depending on the type of surgery, 23 to 48% discontinued acetylic acid
preoperatively, and 80 to 87% always discontinued clopidogrel preoperatively. On average,
platelet inhibition was resumed 4  2.5 days postoperatively. Orthopaedic surgeons
recommenced platelet inhibition earlier than neurosurgeons (p ¼ 0.013). Anticoagulation
with rivaroxabanwasdiscontinued3  2daysbefore surgery.Dependingon the indication,
72 to98%of respondents temporarily replaced traditional anticoagulation therapy (vitamin
K antagonists) with heparin perioperatively.
Conclusion Administration and discontinuation of anticoagulant and platelet-inhibit-
ing medications in the perioperative setting of spinal surgery differ vastly between
different units and surgeons. Recommendations from the spine surgeon societies may
be helpful to develop nationwide guidelines.
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Introduction
Perioperative use of anticoagulant and platelet-inhibiting
agents by patients undergoing spine surgery poses the
dilemma of increased risk of hemorrhage as opposed to an
increased risk of thrombosis or complications by discontinu-
ing patients’ anticoagulant or platelet-inhibiting medica-
tions. The management of perioperative anticoagulant and
platelet-inhibiting agents for patients undergoing spine sur-
gery is a widely discussed topic. Studies have discussed the
controversial topic of increased risk of perioperative hemor-
rhage in patients undergoing treatment with platelet-inhi-
biting agents or low-molecular-weight heparin (LMWH). The
incidence of perioperative hemorrhage reportedly ranges
from 0.1% to 1%.1,2 The study of the risk factors of perio-
perative hemorrhage is difﬁcult because of the rarity of this
complication, thereby leading to contradictory results.
Although some studies report no risk of perioperative
hemorrhage with the use of platelet-inhibiting agents or
LMWH,1,3–7 others indicate a risk.8–10
Another controversial topic in the literature pertains to
the use of LMWH to prevent venous thromboembolic
diseases after spinal surgery. The incidence of deep vein
thrombosis (DVT) in spinal surgery patients is reported
to be 0.3 to 31%, depending on the patient population and
the method of surveillance, and it has been reported to be
considerably lower than that for patients undergoing
major lower extremity surgery.11,12 Therefore, some stu-
dies have reported no need for postoperative LMWH after
spinal surgery.13,14 Others, however, have reported a
decreased incidence of venous thromboembolism after
spine surgery.4,7,15
Survey questionnaires are an excellent tool for examin-
ing current trends and expert opinions. Previous survey
studies of perioperative platelet inhibition or anticoagula-
tion date back to at least 2012, and they were limited to
thromboprophylaxis for spinal surgery, such as the studies
by Glotzbecker et al and Bryson et al,13,16 and perioperative
use of low-dose aspirin for spinal surgery, such as the study
by Korinth et al.17 None of these surveys covered the more
recent issue of new oral anticoagulants for patients under-
going spinal surgery, therapeutic anticoagulation in general,
or bridging anticoagulation. Many recent studies of anti-
coagulation and platelet inhibition in patients undergoing
spinal surgery have been published and might have changed
the practice of spinal surgeons.2–10
Previous studies have yielded contradictory results, and
the recommendations for perioperative management with
anticoagulant and platelet-inhibiting agents for patients
undergoing spine surgery are inconsistent. Therefore, the
aim of this study was to examine the standards of use for
these medications and expert opinions about the subject.
Material and Methods
An online survey was created using the open source survey
tool LimeSurvey, v.2.05 þ . The questionnaire was composed
of 20 questions in four groups covering surgeon experience
with spine surgery, perioperative use of thrombosis prophy-
laxis for spinal surgery, and perioperative management with
anticoagulation and platelet inhibition (Appendix A). The
survey was translated into German and English and
uploaded to http://spinesurvey.limequery.org. Access was
provided by invitation through an e-mail with a token-
activated link. The response values were stored separately
from the list of respondents and Internet protocol addresses.
A list of surgeons involved in spine surgery was obtained
from a list (published online) of all members of the Swiss
Neurosurgical Society (www.swissneurosurgery.ch), a mail-
ing list from the Swiss Society of Spinal Surgery, and a
comprehensive Internet search of all public and private
hospitals in Switzerland employing orthopaedic surgeons
offering spinal surgery. The original list contained 160
surgeons.
For all large neurosurgical or orthopaedic units with
24-hour emergency service (n ¼ 19), one representative of
each neurosurgical and orthopaedic unit who performed
spine surgery was chosen. Most large departments have
departmental policies for the discontinuation and recom-
mencement of anticoagulant and platelet-inhibitingmedica-
tions for spinal surgery patients. One survey study among
neurosurgeons in Germany in 2007 found that 80.3% of
responding neurosurgical units had a written departmental
policy regarding the discontinuation of preoperative acetylic
acid treatment.17 Other doctors on the societies’ lists
employed at these units were excluded because the spine
units were assumed to have uniform standards for perio-
perative use of anticoagulant and platelet-inhibiting medi-
cations. Active in-patient doctors working in private practice
and those who were members of the Swiss Society of
Neurosurgery and the Swiss Society of Spinal Surgery were
also asked to participate in the present survey.
After the exclusions just described and four additional
exclusions due to no available valid e-mail, a list of 110
invitees was uploaded to LimeSurvey. One invitation and up
to ﬁve reminder e-mails were sent from February to
April 2016.
SPSS software v.21 (SPSS Statistics 2010, Chicago, Illinois,
United States) was used for qualitative and quantitative
analyses of the data. Data were split into groups based on
specialty (neurosurgeons and orthopaedic surgeons). Data of
the respondents were analyzed using the Fisher exact test
and various nonparametric tests (Wilcoxon rank sum/Krus-
kal-Wallis and median test) according to the data type and
characteristic. Statistical signiﬁcance was set at p 0.05.
The present article was prepared in accordance with the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement checklist for cross-sec-
tional studies.18
Results
The response rate was 74% for unit representatives and 33%
for surgeons in private practice (►Fig. 1). Twenty-six neu-
rosurgeons and 14 orthopaedic surgeons completed the
questionnaire. The mean experience with spine surgery
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was 17.5  9.3 years for orthopaedic surgeons and 14.5 
9.7 years for neurosurgeons (15.6  9.5 years overall). The
mean number of spinal surgeries per year was 263  118
(range: 100–500) for orthopaedic surgeons and 185  107
(range: 10–500) for neurosurgeons (214  116 overall;
range: 10–500).
Thrombosis Prophylaxis
Twenty-two surgeons (55%) prescribed LMWH on the eve-
ning before surgery. There was no signiﬁcant difference
between neurosurgeons and orthopaedic surgeons (58%
versus 50%, respectively; p ¼ 0.462). Twenty-nine respon-
dents (73%) prescribed compression stockings as part of the
postoperative routine for the prevention of thromboembo-
lism after spinal surgery. Regarding speciﬁc medication for
thrombosis prophylaxis, multiple answers were possible.
Nadroparin (Fraxiparine; Aspen Pharma, Durban, South
Africa) was prescribed by 20 (50%), enoxaparin (Clexane;
Sanoﬁ-Aventis, Paris, France) was prescribed by 18 (45%),
rivaroxaban (Xarelto; Bayer Pharma, Berlin, Germany) was
prescribed by 7 (18%), unfractionated heparin was pre-
scribed by 4 (10%), and dalteparin (Fragmin; Pﬁzer, Pearl
River, New York, United States) was prescribed by 3 respon-
dents (8%).
Medical thrombosis prophylaxis was recommenced
postoperatively for lumbar decompression or lumbar spon-
dylodesis by 38 respondents (95%) and after cervical decom-
pression by 33 (83%). Twenty-eight surgeons (70%)
responded that medical thrombosis prophylaxis was started
6 hours after surgery or during the evening of the day of
surgery, and 10 (25%) responded that it was started on
the ﬁrst postoperative day. LMWH was prescribed by 31
(82%); rivaroxaban was prescribed by 7 (18%). Five sur-
geons (13%) administered thrombosis prophylaxis until
the patient was ambulatory, 29 (76%) administered it until
discharge, 2 (5%) administered it until 1 week postdischarge,
and 2 (5%) administered it > 1 week postdischarge. No sig-
niﬁcant differences were noted between neurosurgeons and
orthopaedic surgeons regarding the thrombosis prophylaxis
prescribed.
Platelet Inhibition
►Table 1 provides the data regarding the practice of pre-
operative discontinuation of platelet inhibition. Platelet
inhibition was discontinued more often before surgeries of
the cervical spine than before those of the lumbar spine. At
the level of the lumbar spine, platelet inhibition was dis-
continued more often for multilevel surgeries or before
spondylodesis than for single-level decompression or dis-
kectomy. On average, platelet inhibition was resumed
4  2.5 days postoperatively, and orthopaedic surgeons
started platelet inhibition (acetylic acid or clopidogrel) sig-
niﬁcantly earlier than neurosurgeons (3  3 days versus
4  2 days postoperatively, respectively; p ¼ 0.013).
Fig. 1 Inclusion/Exclusion ﬂowchart.
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Therapeutic Anticoagulation with Rivaroxaban
Data regarding the practice of preoperative discontinuation
of rivaroxaban are displayed in ►Table 2. If rivaroxaban for
atrial ﬁbrillation was discontinued, then 11 surgeons (28%)
always prescribed bridging anticoagulation therapy with
LMWH, 12 (30%) never prescribed bridging anticoagulation
therapywith LMWH, 13 (33%)made the decision after asking
an internist, and 4 (10%) answered “other.” In cases of DVT/
pulmonary embolism (PE) > 1 year before the planned
spinal surgery, bridging anticoagulation medication to
replace rivaroxaban was always prescribed by 15 surgeons
(38%) and was never prescribed by 8 (20%); 15 (38%) always
made the decision after asking an internist. Nine (22.5%)
routinely ordered serum-anti-Xa activity preoperatively, 23
(57.5%) did not, 6 (15%) ordered it depending on the patient’s
renal function, and 2 (5%) chose the option “other.”
Traditional Anticoagulation Therapy Using Vitamin K
Antagonists
Most respondents paused vitamin K antagonists ((e.g.,
warfarin, Coumadin) after spinal surgery for 1 to 2 weeks.
When vitamin K antagonists where administered for DVT/
PE > 1 year previously or for intermittent atrial ﬁbrillation,
15 to 20% of the respondents did not bridge the antic-
oagulation therapy. ►Table 3 lists the detailed results
regarding the question of whether respondents prescribe
bridging anticoagulation therapy when oral anticoagulants
are paused.
Discussion
The results of this study reveal the rather heterogeneous
practice of perioperative use of anticoagulant and platelet-
Table 1 For the following spine surgery procedures, do you always discontinue acetylsalicylic acid used for platelet inhibition?
Procedure Do you discontinue administra-
tion of acetylic acid for platelet
inhibition before the following
spinal surgeries?
Do you discontinue administration of clopidogrel
for platelet inhibition before the following spinal
surgeries?
Yes No Yes No Only if double
platelet
inhibition
Elective lumbar herniated disk or
spinal canal stenosis: 1 segment (%)
9 (23) 31 (77) 32 (80) 2 (5) 6 (15)
Elective lumbar dorsal interbody
fusion: 1–2 segments (%)
17 (43) 23 (57) 33 (85) 2 (5) 4 (10)
Elective lumbar decompression:
3 segments (%)
16 (40) 24 (60) 33 (82) 2 (5) 5 (13)
Anterior cervical interbody fusion:
1–2 segments (%)
19 (48) 21 (52) 35 (87) 2 (5) 3 (8)
Table 2 Howmany days before the following spinal procedures do you discontinue therapeutic rivaroxaban when it is indicated for
atrial ﬁbrillation?
Procedure Atrial fibrillation History of DVT or PE
All
respon-
dents
Neuro-
surgeons
Ortho-
paedic
surgeons
p All respon-
dents
Neuro-
surgeons
Ortho-
paedic
surgeons
p
Elective lumbar
herniated disk or spinal
canal stenosis:
1 segment
3.1  2.0 2.6  1.3 4.2  2.9 0.12 3.3  2.0 2.8  1.3 4.5  2.8 0.07
Elective lumbar dorsal
interbody fusion:
1–2 segments
3.2  2.0 2.6  1.3 4.4  2.8 0.05 3.4  2.0 2.8  1.3 4.7  2.6 0.03
Elective lumbar
decompression:
3 segments
3.2  2.0 2.6  1.3 4.4  2.8 0.06 3.4  2.0 2.8  1.3 4.5  2.8 0.08
Anterior cervical
interbody fusion:
1–2 segments
3.1  2.0 2.6  1.3 4.2  2.9 0.14 3.4  2.0 2.8  1.3 4.6  2.7 0.05
Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism.
Note: Data are presented as mean plus or minus standard deviation (days).
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inhibiting medications among spine surgeons. Among the
respondents, 55% prescribed prophylactic anticoagulation
preoperatively; there was no signiﬁcant difference between
orthopaedic surgeons (50%) and neurosurgeons (58%). Bry-
son et al reported that 31% of orthopaedic surgeons and 73%
of neurosurgeons routinely used LMWH.16 The incidence of
DVT is reported to be 0.3 to 31% for patients who undergo
spinal surgery.11,12,15 One reason for the wide range in the
incidence of DVT is the method used to diagnose this con-
dition. If diagnosed with ultrasonography, there is a high
incidence of asymptomatic DVT, as reported by Yamaguchi
et al.12 The symptomatic incidence of DVT is reported to be
 1 to 3%.4,11,14,19
Cox et al reported consequent chemical thrombosis pro-
phylaxis for all patients undergoing spine surgerywithout an
increased risk of morbidity and a DVT rate of 1%.4 In contrast,
a large reviewcould not support or refute the use of chemical
thrombosis prophylaxis in addition to compression stock-
ings.11 Among our respondents, 95% prescribed chemical
thrombosis prophylaxis postoperatively and 73% prescribed
compression stockings as part of the postoperative routine
for the prevention of thromboembolism after spinal surgery.
No signiﬁcant differences in the use of thrombosis prophy-
laxis between neurosurgeons and orthopaedic surgeons
were found. Regarding the time to start thrombosis prophy-
laxis, Strom et al recommended starting thrombosis pro-
phylaxis 24 to 36 hours postoperatively, with a very low
hemorrhage risk.7 In a survey by Glotzbecker et al, the
average time to start thrombosis prophylaxis was 48 hours
after surgery.13 Among our respondents, 70% started throm-
bosis prophylaxis on the day of surgery.
Only  1 of 5 respondents discontinued platelet inhibi-
tion with acetylic acid before elective lumbar herniated disk
or stenosis. However, most of our respondents ceased
clopidogrel preoperatively. Surprisingly, even for cervical
hernia surgery, less than half would cease acetylic acid
preoperatively. Park et al recommended that acetylic acid
should be discontinued 7 days before surgery.10 Similarly, in
the survey study by Korinth et al published in 2006,
most German neurosurgeons (95%) ceased low-dose aspirin
before elective spine surgery, on average, 7 days preopera-
tively.17 Cuellar et al showed no appreciable increase in
bleeding-related complication rates for patients with car-
diac stents undergoing spine surgery who continued using
aspirin compared with inpatients who discontinued aspirin
before surgery.5
A 2016 study by Soleman et al demonstrated no
increased risk of postoperative hemorrhage if acetylic acid
was continued by patients who underwent noninstru-
mented extradural lumbar spinal surgery; they concluded
that its continuation seemed safe and therefore should
be recommended.6 Another study similarly showed no
increased risk of postoperative spinal bleeding, even in a
subgroup who underwent double platelet inhibition with
aspirin and clopidogrel.3 These results might explain the
much lower percentage of spinal surgeons who discontin-
ued acetylic acid before elective spine surgery in the current
study compared with the survey in Germany performed
Table 3 In the following cases, do you use heparin while discontinuing vitamin K antagonists perioperatively?
Procedure Yes (%) Rather yes (%) Rather no (%) No (%) 95% confidence
interval; p valuea
DVT/PE within
last 6 mo
All respondents 32 (82) 6 (15) 1 (3) – 0.205 to 1.227; 0.162
Neurosurgeons 20 (77) 6 (23) – –
Orthopaedic surgeons 12 (86) – 1 (8) –
DVT/PE > 1 y ago All respondents 20 (51) 8 (21) 8 (21) 3 (7) 0.300 to 1.538; 0.187
Neurosurgeons 13 (50) 6 (23) 5 (19) 2 (8)
Orthopaedic surgeons 7 (54) 2 (15) 3 (23) 1 (8)
Intermittent atrial
ﬁbrillation
All respondents 22 (56) 8 (21) 6 (15) 3 (8) 0.135 to 1.659; 0.096
Neurosurgeons 15 (58) 6 (23) 3 (11) 2 (8)
Orthopaedic surgeons 7 (54) 2 (15) 3 (23) 1 (8)
Mechanical aortic
valve implant
All respondents 34 (87) 4 (10) 1(3) – 0.019–1.456; 0.044
Neurosurgeons 23 (88) 2 (8) 1 (4) –
Orthopaedic surgeons 11 (85) 2 (15) – –
Mechanical mitral
valve implant
All respondents 34 (87) 4 (10) 1(3) – 0.019–1.456; 0.044
Neurosurgeons 23 (88) 2 (8) 1 (4) –
Orthopaedic surgeons 11 (84) 2 (15) – –
Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism.
aOrdinal regression; 95% conﬁdence interval and signiﬁcance (p value).
Note: Data are presented as n (%). 1 Nonrespondent for all items. p values for the difference between the neurosurgical and orthopaedic group.
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10 years previously by Korinth et al.17 If discontinued, ortho-
paedic surgeons reestablished platelet inhibition (aspirin or
clopidogrel)  1 day earlier than neurosurgeons (p ¼ 0.013).
Steinberg et al showed a higher rate of bleeding if bridging
anticoagulation therapy was used during perioperative
interruption of platelet inhibition treatment.20 Regarding
cessation of therapeutic anticoagulation with rivaroxaban, a
similarly size group of respondents chose to always or never
use bridging anticoagulation therapy. On average, respon-
dents ceased therapeutic rivaroxaban slightly more than
3 days before surgery, in accordancewith themanufacturer’s
recommendation. Orthopaedic surgeons ceased rivaroxaban
earlier than neurosurgeons.
Unlike therapeutic anticoagulation with rivaroxaban and
platelet inhibition, therapeutic anticoagulationwith vitamin
K antagonists was stopped and replaced with bridging antic-
oagulation therapy by most orthopaedic surgeons and neu-
rosurgeons. This was the case for patients with mechanical
aortic valve, mechanical mitral valve, and DVT/PEwithin the
past 6months. If the reason for vitamin K antagonist usewas
DVT or PE > 1 year before or for atrial ﬁbrillation, 23 to 28%
would rather not prescribe bridging anticoagulation therapy,
which was similar to the practice for platelet inhibitors. No
difference was found for orthopaedic surgeons and neuro-
surgeons regarding the use of bridging anticoagulation ther-
apy for ceased vitamin K antagonists.
Douketis et al reported no need for perioperative bridging
therapy for interrupted therapeutic anticoagulation with
warfarin for patients with atrial ﬁbrillation.8 They found
that the arterial thromboembolic risk after cessation of
therapeutic anticoagulation was equal to that when no
bridging anticoagulation therapy was administered; how-
ever, the risk of hemorrhage was increased when bridging
anticoagulation therapy was used. They also stated that the
use of bridging anticoagulation therapy has been anchored to
the premise that the associated higher bleeding risk was
clinically acceptable because it would be offset by a lower
risk of perioperative arterial thromboembolism.8
The main limitation of the present study was the low
response rate of invitees from private practices. However,
the response rate by the unit representatives was excellent
for an online-based survey. The overall response rate of 41%
was slightly lower than that of other surveys among spine
surgeons that reported response rates of 49 to 67.6%.13,17
The survey was performed in only one country that
might have limited the generalizability of the results. The
responses were anonymized so the respondents’ names and
the response sets were stored in different ﬁles. Therefore,
the differences between the units involved in spine surgery
and surgeons in the private practice could not be
established.
Direct evaluation of complications (hemorrhage/DVT/PE)
related to different perioperative anticoagulation practices
could not be performed through a survey. These complica-
tions have a very low incidence, and the long experience of
the responding surgeons did not suggest that they would
continue riskier practice if they experienced higher compli-
cation rates.
This survey study adds a comprehensive overview of
current practice regarding the use of anticoagulant and
platelet-inhibiting medications in the perioperative setting
of elective spinal surgery. To date, it is the ﬁrst survey among
spinal surgeons regarding this subject in the past 5 years, and
it is also the most comprehensive. In contrast to previous
surveys, it included the use of platelet inhibition and
anticoagulation.
Furthermore, it is the ﬁrst survey examining current
standards for the use of new oral anticoagulants—in this
case, the most widely used example is rivaroxaban—and
bridging anticoagulation therapy for spinal surgery. The
results were similar to those of previous survey studies of
heterogeneous practice with regard to perioperative use of
anticoagulant and platelet-inhibiting medications for elec-
tive spinal surgery patients. However, they also demon-
strated that newer results reported in the literature might
have inﬂuenced the current practice in this ﬁeld even those
there is still very little evidence.
Conclusions
Administration and discontinuation of anticoagulant and
platelet-inhibiting medications in the perioperative setting
of spinal surgery differ vastly between different units and
surgeons. Recommendations or a protocol from the National
Spine Surgeon Society may be helpful to develop nationwide
guidelines.
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Survey Spine Surgery
Due to a lack of evidence, many clinical decisions in spine
surgery are made based on rather than evidence. For exam-
ple, for the use of thrombosis prophylaxis pre-, peri-, and
postoperatively as well as the discontinuation of thrombo-
cyte inhibitors and oral anticoagulants for elective spine
surgery, no common guidelines exist.
Because a prospective randomized controlled study to
examine these issues is not feasible, we conducted a survey
among all spine surgeons (neurosurgeons and orthopaedic
surgeons) in Switzerland. Our goal was to examine simila-
rities and differences of expert opinions with regard to the
subjects just described.
The questionnaire takes  10 minutes to complete. All
informationwill be treated conﬁdentially, Internet protocols,
e-mails, and nameswill be stored in a separate database from
the answers.
Start
What medical specialty are you certiﬁed in?
Please choose only one of the following:
• Neurosurgery
• Orthopaedics
• Neurosurgery and orthopaedics
• Other
How many years of clinical experience as a certiﬁed
specialist do you have?
Only numbers may be entered in this ﬁeld.
Please write your answer here: __
How many spinal surgeries do you perform annually?
Only numbers may be entered in this ﬁeld.
Please write your answer here: __
Thrombosis prophylaxis
Which medical thrombosis prophylaxis do you
prescribe?
Please choose all that apply:
• Fraxiparin
• Clexane
• Xarelto 10 mg
• Liquemin
• Other:
Are compression stockings a part of your spinal
surgery patients’ postoperative routine?
Please choose only one of the following:
• Yes
• No
For the following spinal procedures, do you prescribe
prophylactic low molecular heparin on the evening
presurgery?
Please choose the appropriate response for each item:
Yes Uncertain No
Elective lumbar removal of herniated
disk or decompression (1 segment)
Elective lumbar interbody
fusion (1–2 segments)
Elective lumbar decompression
3 segments
Elective anterior cervical
diskectomy (1–2 segments)
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For the following spine surgery procedures, do you
prescribe prophylactic low molecular heparin
postoperatively?
After straightforward elective spine procedures,
when do you begin prophylactic low molecular
heparin?
Please choose only one of the following:
• 6 h postsurgery
• The evening after surgery
• The evening of the first postoperative day
• Other
For elective spine procedures, when do you start
Xarelto (Rivaroxaban) postoperatively?
Only answer this question if the following conditions are
met:
Answer was ‘Xarelto 10 mg’ at question ’4 [Medi]’ (Which
medical thrombosis prophylaxis do you prescribe?)
Please choose only one of the following:
• 6 h postsurgery
• The evening of the day of surgery
• The evening of the first postoperative day
• Change from low molecular heparin to Xarelto on the
day of discharge
• Other
When do you cease postoperative prophylactic low
molecular heparin?
Please choose only one of the following:
• When the patient is ambulatory
• When the patient is discharged home
• Up to 1 wk postdischarge
• Later than 1 wk postdischarge
• Other
Platelet-inhibiting medications
For the following spine surgery procedures, do you
always discontinue acetylsalicylic acid used for
platelet inhibition?Please choose the appropriate response for each item:
Yes Uncertain No
Elective lumbar
removal of herniated
disk or decompression
(1 segment)
Elective lumbar
interbody fusion
(1–2 segments)
Elective lumbar
decompression 3
segments
Elective anterior
cervical diskectomy
(1–2 segments)
Please choose the appropriate response for each item:
Yes No
Elective lumbar removal
of herniated disk or
decompression
(1 segment)
Elective lumbar interbody
fusion (1–2 segments)
Elective lumbar
decompression
3 segments
Elective anterior cervical
diskectomy
(1–2 segments)
Do you discontinue Clopidogrel (Plavix) before the
following spine procedures?
Please choose the appropriate response for each item:
Yes No Only if
patients
have
aspirin
and Plavix
Elective lumbar
herniated disk
removal or
decompression
(1 segment)
Elective lumbar
interbody fusion
(1–2 segments)
Elective lumbar
decompression
3 segments
Elective anterior
cervical diskectomy
(1–2 segments)
Journal of Neurological Surgery—Part A
Perioperative Anticoagulant and Platelet-inhibiting Medications Baschera et al.
D
ow
nl
oa
de
d 
by
: U
ZH
 H
au
pt
bi
bl
io
th
ek
 / 
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
When do you usually restart platelet inhibition postoperatively (in days)?
Only an integer value may be entered in this field.
Please write your answer here: __
Oral anticoagulation
How many days before the following spinal procedures do you discontinue therapeutic Rivaroxaban (Xarelto)
when it is indicated for atrial ﬁbrillation?
If you discontinue Xarelto in patients with atrial ﬁbrillation, are you prescribing low molecular heparin
temporarily?
Please choose only one of the following:
• Yes
• No
• I always consult a internist
• Other
How many days before the following spinal procedures would you discontinue therapeutic Xarelto in patients
with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) in the past?
Do you preoperatively measure serum anti-Xa-activity when Xarelto is discontinued according to the
manufacturer’s recommendations?
Please choose all that apply:
• Yes
• No
• Depending on the kidney function of the patient
• Other:
Please choose the appropriate response for each item:
1 2 3 4 5 6 7 8 9 10
Elective lumbar removal of herniated disk or
decompression (1 segment)
Elective lumbar interbody fusion (1–2 segments)
Elective lumbar decompression 3 segments
Elective anterior cervical diskectomy (1–2 segments)
Please choose the appropriate response for each item:
1 2 3 4 5 6 7 8 9 10
Elective lumbar removal of herniated disk or
decompression (1 segment)
Elective lumbar interbody fusion (1–2 segments)
Elective lumbar decompression 3 segments
Elective anterior cervical diskectomy (1–2 segments)
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When discontinuing therapeutic dose Xarelto preoperatively in patients with history of DVT/PE (>1 year ago),
do you use low molecular heparin as a temporary replacement?
Please choose only one of the following:
• Yes
• No
• Always consulting an internist
• Other
For how long after the following spinal procedures do you discontinue oral anticoagulants (Marcoumar,
warfarin)?
In the following cases, do you use heparin while discontinuing Vitamin K antagonists perioperatively?
Please choose the appropriate response for each item:
<1 wk 1–2 wk 2–3 wk 3–4 wk > 4 wk
Elective lumbar herniated disk or decompression (1 segment)
Elective lumbar interbody fusion (1–2 segments)
Elective lumbar decompression 3 segments
Elective anterior cervical diskectomy (1–2 segments)
Please choose the appropriate response for each item:
Yes Rather yes Rather no No
If for the indication deep vein thrombosis (DVT)/pulmonary
embolism (PE) within the last 6 mo
if for the indication DVT/PE > 1 y in the past
if for the indication intermittent atrial ﬁbrillation
if for the indication mechanical aortic valve implant
if for the indication mechanical mitral valve implant
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